ClinicalTrials.gg
RecruitingNCT05743179Zoo-PUpdated Feb 20, 2024

The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients

A Phase 4 interventional study of Zoledronate in Hip Fractures and Pneumonia, sponsored by The University of Hong Kong. Recruiting at 5 sites in Hong Kong. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by The University of Hong Kong · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,692
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hip Fractures with a site in Hong Kong — 3 open to participants now, 4 under way, none of them phase 3. Hip Fractures · Hong Kong.

Planned enrollment
2nd of 11
2,692 · median 126
Started
2022
with 1 other
Phase 4
2 of 13
1 open now
Registered
12th of 13
by date
Lead sponsor
2 of 13
The University of Hong Kong

Among the 13 studies in Hip Fractures with a site in Hong Kong, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 12th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

3 of the 13 studies in Hip Fractures with a site in Hong Kong are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hip Fractures with a site in Hong Kong, or all of them as a file.
02

Study summary

Nitrogen-containing bisphosphonates (N-BPs; such as alendronate and zoledronate) are commonly used in the treatment of osteoporosis and fracture prevention, in which zoledronate has a proven better efficacy than alendronate. In 2018, our real-world propensity score matched study showed that the use of N-BPs was significantly associated with reduced risk of myocardial infarction and stroke in hip fracture patients. In addition to cardiovascular diseases, both preclinical study and sensitivity analysis also suggest evidence for N-BPs in pneumonia prevention. Moreover, a pragmatic clinical trial is developed to evaluate effect of the tested intervention in real-life routine clinical practice since traditional explanatory radomised controlled trial (RCT) may have poor generalizability due to highly selected patients and controlled environments. This study aims to evaluate if zoledronate reduces risk of pneumonia in hip fracture patients using pragmatic clinical trial approach.

This is an open-label, multi-centre, pragmatic, randomised controlled trial. Patients will be recruited from 4 hospitals, namely Caritas Medical Centre, Prince of Wales Hospital, Queen Mary Hospital, and United Christian Hospital. Age, sex, body mass index, eGFR, history of fracture, chronic respiratory diseases, and other medical history, will be measured and recorded at recruitment.

Read the detailed description

N-BPs are widely used in the treatment of osteoporosis and fracture prevention. Although alendronate is the first-line antiosteoporosis medication in many countries, it is associated with esophageal and gastrointestinal irritation. In addition, the regimen for alendronate is one tablet per week and careful use of alendronate is required to avoid gastrointestinal irritation (e.g. take the tablet on an empty stomach, stay upright for at least 30 minutes after taking the medication), leading to relative low drug compliance. On the other hand, the regimen of zoledronate is 5mg infusion once a year. Since the route of administration is intravenous infusion, it avoids the gastrointestinal irritation problem. In terms of fracture prevention, zoledronate has a proven better efficacy than alendronate. Most importantly, previous HORIZON recurrent fracture trial showed that zoledronate use reduced risk of mortality in addition to fracture prevention. Thus, zoledronate is considered the most efficacious N-BP in clinical use.

N-BPs could exert extra-skeletal beneficial effects. In 2018, our real-world propensity score matched study (N=34,991) using the Clinical Data Analysis and Reporting System (CDARS), a clinical database managed by the Hong Kong Hospital Authority, showed that use of N-BPs was significantly associated with reduced risk of myocardial infarction and stroke in hip fracture patients. Later in the same year, a randomized controlled trial (RCT) in 2,000 osteopenic women showed that zoledronate may reduce risk of myocardial infarction with an odds ratio of 0.61 (95% CI: 0.36-1.02) after following up for 6 years. They subsequently performed a detailed post-hoc analysis and showed that zoledronate use was significantly associated with reduced risk of myocardial infarction, composite cardiovascular end-point, and fatal stroke. This example demonstrated not only the extra-skeletal effect of N-BPs, but also showed that high-quality real-world data with state-of-the-art statistical method could potentially be useful in causal inference.

In addition to cardiovascular diseases, N-BPs may be useful in preventing pneumonia. Preclinical study showed that N-BPs are anti-inflammatory and may modulate macrophages in response to pneumonia. In addition, pharmacokinetic studies showed that the highest concentration of N-BPs was detected in trachea other than bone after oral ingestion or intravenous infusion of N-BPs. Among various N-BPs, alendronate was detected in the trachea with a concentration of 607 ng/ml 72 hours after oral ingestion, which was almost half of the concentration (1370 ng/ml) detected in vertebrae. Thus, we conducted a real-world population-based propensity score matched study in a cohort of 54,047 hip fracture patients to investigate the association of N-BP use with risk of pneumonia. Among hip fracture patients, N-BP use was significantly associated with 24% risk reduction in pneumonia (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.70-0.83), with an absolute risk difference of 2%. Similar significant association was observed for pneumonia mortality. To further reduce the potential bias of confounding by indication, we performed a sensitivity analysis by including users of other anti-osteoporosis medications in the control group, instead of patients without using any anti-osteoporosis medications. A similar significant association was observed. In agreement with the preclinical studies, we provided evidence for N-BPs in pneumonia prevention. This finding attracted wide media coverage, including Reuters and the New York Times.

Although utilisation of real-world data is an emerging approach in evaluating drug effectiveness, RCT is still considered the gold standard in evaluating drug efficacy. However, traditional explanatory RCT may have poor generalizability due to highly selected patients and controlled environments. Thus, pragmatic clinical trial is developed to evaluate if the tested intervention is effective in real-life routine clinical practice, by reducing bias using randomization and improving generalizability using real-world setting. We aim to evaluate if zoledronate reduces risk of pneumonia in hip fracture patients using pragmatic clinical trial approach.

03

Conditions studied

  • Hip Fractures
  • Pneumonia

Keywords

  • Zoledronic Acid
  • Pneumonia
  • Hip Fractures
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 60 years
  • With recent fragility hip fracture at proximal femur
  • Have the ability to understand the requirements of the study, provide written , including consent for the use and discloser of research-related health information, and comply with the study data collection procedures. Provide signed and dated informed consent form

Exclusion criteria

Exclusion Criteria:

  • Known to be hypersensitive to any N-BPs
  • Estimated (eGFR) \< 30 ml per minute per 1.73 m2 of body surface area
  • Regular user of anti-osteoporosis medications (including bisphosphonates, denosumab, teriparatides, and raloxifene) or oral or intravenous systemic in the previous year.
  • Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,692 participants (estimated)

Study arms

  • Experimental
    Zoledronate

    Zoledronate intravenous infusion (5mg) once and usual care will be provided to the patient and mark the start of 12-month follow-up period

    Drug: Zoledronate

  • No intervention
    Control

    Only usual care will be provided to the patient with 12-month follow-up period.

Interventions

06

What researchers measure

Primary outcomes

  1. Pneumonia hospitalizations

    Diagnosis records of pneumonia from electronic medical records

    Time frame: 12 months

Secondary outcomes

  1. Cardiovascular events

    Diagnosis records of cardiovascular events from electronic medical records

    Time frame: 12 months

  2. Refracture events

    Diagnosis records of refracture from electronic medical records

    Time frame: 12 months

  3. Problems associated with fracture healing, including revision surgery

    Diagnosis and operation records from electronic medical records

    Time frame: 12 months

  4. All-cause mortality

    Date of death and cause of death information from electronic medical records

    Time frame: 12 months

07

Study locations

4 of 5 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will be shared upon special request to the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for May 2025, 29 months after the start.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 29 months is above that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 24, 2023
StartActual
Dec 5, 2022
Primary completionEst.
May 2025
CompletionEst.
Jun 2025
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743179
Collaborators
Queen Mary Hospital, Hong Kong, Caritas Medical Centre, Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, United Christian Hospital
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Dec 5, 2022
Primary completion
May 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Feb 20, 2024

Study contacts

Ching-Lung Cheung, PhD
Contact
lung1212@hku.hk
+852 2831-5080
Kathryn Tan, MD
principal investigator · The University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoledronic Acid

Start the discussion